Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) (STAR)

This study has been completed.
Information provided by:
Abbott Identifier:
First received: September 13, 2005
Last updated: July 11, 2008
Last verified: June 2008
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Condition Intervention Phase
Metabolic Syndrome
Drug: trandolapril/verapamil
Drug: (Hyzaar) losartan/hydrochlorothiazide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Oral Glucose Tolerance [ Time Frame: up to 1 year / 52 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in blood pressure (BP), pulse rate and BP control. HbA1c, insulin sensitivity, insulin release, albuminuria, lipid profile, AMBP, clinical safety labs and adverse events. [ Time Frame: up to 1 year / 52 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 280
Study Start Date: March 2004
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: trandolapril/verapamil
2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
Other Names:
  • Tarka
Active Comparator: 2 Drug: (Hyzaar) losartan/hydrochlorothiazide
50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
Other Names:
  • Hyzaar
  • losartan/hydrochlorothiazide


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metabolic syndrome
  • Fasting blood glucose between 100 mg/dL and 125 mg/dL
  • Hypertension
  • One additional criteria, Exclusion 1

Exclusion Criteria:

  • Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus.
  • Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00234858

Sponsors and Collaborators
Study Director: Global Medical Information Abbott
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Peter Bacher, MD, PhD, Abbott Identifier: NCT00234858     History of Changes
Other Study ID Numbers: M03-598 
Study First Received: September 13, 2005
Last Updated: July 11, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
Metabolic Syndrome

Additional relevant MeSH terms:
Metabolic Syndrome X
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Calcium Channel Blockers
Vasodilator Agents processed this record on October 25, 2016